News

The randomized, double-blind, vehicle controlled phase 3 confirmatory study included 744 patients. The primary endpoint of statistically significant improvement in Schirmer's score (a measurement of tear production) was

The clinical trial is evaluating the efficacy and safety of Quisinostat in platinum-resistant ovarian cancer in combination with Paclitaxel and Carboplatin. The detailed results will be presented in

Cannabics Pharmaceuticals chief scientist Eyal Ballan stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on

Charles Theuer, M.D., Ph.D., President and CEO of TRACON, said: “The SPA agreement represents a significant milestone for TRACON, as it provides us with a clearly defined development

The investment was led by C-Bridge Capital, joined by a number of new investors including QianHai Equity Investment FOF, FOCUS Media Jiangnanchun Foundation, WTT Investment, together with the

Ganaxolone is being developed in three different dose forms that include IV, capsule, and liquid, aimed at maximizing therapeutic reach to adult and pediatric patient populations in both acute and chronic

The 16-subject FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial will assess 50 mg of CBD in ZYN002 4.2% gel once daily. It

Upon completion of the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of BiondVax. Angels Investments is owned by Check Point co-founder and

Together the two companies are projected to generate approximately $136 million dollars in revenue in 2016 and are projecting $156 million in revenue for 2017. F.A.S.T. will retain